Population-Based Screening Can ID Children Who Progress to Clinical T1D

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on June 2, 2026.

via HealthDay

TUESDAY, June 2, 2026 -- Population-based screening for early-stage type 1 diabetes identifies most children who progress to clinical type 1 diabetes, with additional cases detected with repeat screening, according to a study published online May 21 in the Journal of the American Medical Association.

Christiane Winkler, Ph.D., from the German Research Center for Environmental Health in Munich, and colleagues estimated early-stage (stage 1 or 2) type 1 diabetes prevalence and disease progression to clinical (stage 3) type 1 diabetes in a population-based screening study involving 220,476 children. Screening was conducted once in children aged 1.75 to 5.99 years until March 2019 and was then expanded to up to two screenings in children aged 1.75 to 10.99 years.

Overall, 590 children had presymptomatic early-stage type 1 diabetes at first screening (adjusted population frequency, 0.3 percent; prevalence, 0.23 and 0.06 percent for stage I and stage II type 1 diabetes, respectively). The researchers identified 29 additional cases in repeat screening in 11,726 children after a median of 3.3 years. Overall, stage 3 diabetes developed in 212 children with an early-stage diagnosis at first screening, five with a diagnosis at rescreening, and 43 without early-stage diagnosis during a median follow-up of 5.7 years. The five-year progression from early-stage to clinical diabetes was 36.2 percent, with no significant difference for children with and without first-degree family history.

"These data show that screening in the general population makes sense," Winkler said in a statement. "If we only test children with a family history of type 1 diabetes, we miss the majority of children who later develop stage 3 type 1 diabetes."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-06-03 03:42

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords